Betterlife Pharma Inc. · CSE:BETR
Betterlife Pharma — Investor Presentation (January 2023)
15 slides from Betterlife Pharma's investor presentation, Jan 13, 2023
Slide 1: Working to build a BetterLife, with innovative medicines
Working to build a BetterLife, with innovative medicines. BetterLife strives to deliver breakthrough, patient-friendly, safe, non-hallucinogenic medicines to treat the unmet psychiatric conditions and the neurological disorders. CSE: BETR OTCQB: BETRF BetterLife Pharma / 01
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. BetterLi
Slide 3: Investment Highlights
Vision: To deliver patient-friendly mental health solutions by producing unregulated, economical, curative, and safe prescription medicines for the global market. Team: Highly experienced pharma team with significant track record in developing & commercializing successful therapeutics. Investment Hi
Slide 4: A Fast Growing Problem - Worldwide Mental Disorder
Mental Disorder More and more people are suffering from mental disorders. In a forecast by Mordor Intelligence, the global antidepressants market alone is expected to grow at a CAGR of 2.68% during the forecast period of 2019-2027. Today‘s business and life culture is demanding more and more commitm
Slide 5: BETR-001 – A promising Solution
BETR-001 – A promising Solution In the last 10 years, psychedelics have again BetterLife has set out to develop a non- been intensively researched. More and more hallucinogenic medicine that will have the studies are showing the potential benefits positive effects of psychedelics but will of psyched
Slide 6: BETR-002
BETR-002 A novel formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound, with potential for treatment of benzodiazepine dependency, anxiety, and other neurological disorders. Its active pharmaceutical ingredient is dihydrohonokiol-B (“DHH-B”). DHH-B is a derivative of honokiol
Slide 7: Indications: Major Depression Disorder (MDD)
Indications Major Depression Disorder (MDD) Mental disorder characterized by a sustained feeling of sadness or loss of pleasure and or interest in life. Economic Burden worldwide to be about $1 trillion/year. Approximately 280 million people in the world have depression. (1) DEPRESSION IS A LEADING
Slide 8: Indications: Anxiety Disorder (AD)
Indications Anxiety Disorder (AD) Intense, excessive and persistent worry and fear about everyday situations. Often, anxiety disorders involve repeated episodes of sudden feelings of intense anxiety and fear or terror that reach a peak within minutes (panic attacks). 12 Billion workdays are lost, ev
Slide 9: Indications: Neuropathic Pain (NeP)
Indications Neuropathic Pain (NeP) Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. The origin of neuropathic pain is diverse and related to a large variety of often difficult to treat underlying diseases or lesions. Symptoms include localized or widespread
Slide 10: Indications: Benzodiazepine Dependency (BZD)
Indications Benzodiazepine Dependency (BZD) Class of drugs used to tranquilize symptoms of anxiety, panic disorders, insomnia, muscle tension and seizures. Usually prescribed for short- term relief over a few weeks because it is highly addictive. Benzodiazepines Market size is projec- ted to reach U
Slide 11: Program Planning
Program Planning Program Discovery Preclinical IND Phase I Phase II Phase III Major Depressive Disorder BETR-001 Anxiety Disorder BETR-001 Neuropathic Pain BETR-001 Benzodiazepine Dependency BETR-002 BetterLife Pharma / 11
Slide 12: Market
Global sales of psychiatric drugs could reach more than $40bn by 2025. According to GlobalData, sales of psychiatric drugs are expected to increase from US$ 27.4 billion in 2020 to US$ 40.9bn in 2025, growing at a compound annual growth rate (CAGR) of 8.4%. Market Global annual sales forecast of dru
Slide 13: Management Team
Management Team BetterLife Pharma /
Slide 14: Management Advisors
Hooshmand Sheshbaradaran, PhD Management Chief Operating Officer Anthony Calandra, PhD 30+ years senior pharma executive drug Head Regulatory development, operations, licensing and M&A 30+ years of pharmaceutical and regulatory affairs Ahmad Abdi Ghaffari, PhD Doroudian, Head of Preclinical PhD Rese
Slide 15: Thank you. Contact
Thank you. Contact Ahmad Doroudian, Ph.D. CEO and Director BetterLife Pharma Inc. ahmad.doroudian@blifepharma.com David Melles IR Manager David.Melles@blifepharma.com https://abetterlifepharma.com/ LinkedIn Twitter Instagram BetterLife Pharma / 15
BetterLife Pharma — Investor Presentation (January 2023) on 6ix